TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27029363
Drug: High exposed
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exposed group (average concentration of cadmium >0.40 mg/kg in rice and >1.0 mg/kg in soil)
Study: 27029363
Drug: Low exposed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low exposed group (average concentration of cadmium 0.15-0.40 mg/kg in rice and 0.5-1.0 mg/kg in soil)
Study: 25398670
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype of rs324148
Study: 25398670
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype of rs9394992
Study: 20492853
Drug: Higher-dose paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Higher-dose paliperidone ER (12 mg/d)
Study: 20492853
Drug: Lower-dose paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lower-dose paliperidone ER (6 mg/d)
Study: 20492853
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER (both doses)
Study: 18954708
Drug: Low-dose CBCT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CBCT imaging
Study: 8800307
Drug: Cadexomer iodine
Normalized name: Cadexomer Iodine
DrugBank: Cadexomer iodine (DB16572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadexomer iodine ointment (Iodosorb)
Study: 8800307
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (gentamicin solution, streptodornase/streptokinase, or dry saline gauze)
Study: 1320306
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (720 EIU, 3 doses, 0, 1 month schedule, booster at month 6)
Study: 1320306
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (3 consecutive lots)
Study: 6480953
Drug: Doxepin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (10 mg three times daily)
Study: 6480953
Drug: Cyproheptadine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (4 mg three times daily)
Study: 6480953
Drug: Hydroxyzine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (10 mg three times daily)
Study: 6480953
Drug: Cinnarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (10 mg three times daily)
Study: 26973262
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 8 weeks in addition to routine postoperative treatment
Study: 26973262
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative treatment only (Control)
Study: 22773286
Drug: Antenatal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal treatment of maternal periodontitis
Study: 22773286
Drug: Postpartum treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum treatment of maternal periodontitis
Study: 21733413
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program from a clinical pharmacist
Study: 16675610
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mug once daily for 7-10 days
Study: 12001701
Drug: Immunoablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoablative therapy including high dose cytotoxic agents and hematopoietic autologous stem‐cell rescue
Study: 12001701
Drug: Non‐myeloablative allogeneic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐myeloablative allogeneic transplantation and sub‐myeloblative high dose cyclophosphamide without stem cell support
Study: 9572809
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (0.75 g/kg body wt)
Study: 8586807
Drug: NG‐monomethyl‐L‐arginine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (250 mg by intravenous infusion for 5 min)
Study: 779796
Drug: Cyclophosphamide (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (average dose: 1.8 mg/kg/day)
Study: 27842926
Drug: No jejunal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No jejunal supplement (Control)
Study: 23329881
Drug: neoadjuvant chemotherapy+rh‐endostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy+rh‐endostatin
Study: 17277036
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vildagliptin daily
Study: 17277036
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vildagliptin daily
Study: 15489367
Drug: Low fluoride
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluoride mouthrinse/toothpaste treatment regime
Study: 15489367
Drug: Non-active control
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active control combination
Study: 11574431
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (multiple daily injections or continuous subcutaneous infusion with frequent blood-glucose testing)
Study: 11574431
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (1-2 injections of insulin per day)
Study: 11574431
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy and Conventional therapy
Study: 9316669
Drug: Clonazepam (0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5-2.5 mg/day)
Study: 28035016
Drug: Esmolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol infusion (160 mg, range 110-200 mg in the 5 min before exercise)
Study: 22365565
Drug: Propranolol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol infusion
Study: 28035016
Drug: Esmolol maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol maintenance infusion (0.2 mg·kg total body mass-1·min-1)
Study: 28035016
Drug: Esmolol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol and saline infusion during epinephrine infusion
Study: 26046585
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of water
Study: 21221002
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous glucose monitoring
Study: 18641196
Drug: Weekly folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly folic acid supplementation (5000 or 2800 microg)
Study: 18641196
Drug: Daily folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily folic acid supplementation (400 or 200 microg)
Study: 18641196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily and weekly iron, zinc, and vitamin B‐12 provided)
Study: 12048138
Drug: Bezafibrate treatment
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate treatment
Study: 30338680
Drug: Robuvit 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robuvit 300 mg/day
Study: 27001568
Drug: Farletuzumab 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farletuzumab 1.25 mg/kg
Study: 27001568
Drug: Farletuzumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Farletuzumab 2.5 mg/kg
Study: 21486536
Drug: Dutasteride (2mg/g)
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride (2mg/g)
Study: 21486536
Drug: Progesterone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (40 mg)
Study: 12099160
Drug: Policosanol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol (5 mg/day, increased to 10 mg/day if total cholesterol > 6.1 mmol/L after 6 months)
Study: 28099300
Drug: Plate fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plate fixation and Nonoperative treatment
Study: 12750100
Drug: argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon green laser treatment (multiple 100‐micro m spots at least 750 micro m from the center of the fovea)
Study: 12750100
Drug: argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon green laser treatment
Study: 12750100
Drug: argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: argon green laser treatment (higher-intensity laser burns)
Study: 12750100
Drug: choroidal neovascularization
Normalized name: Antineovascularisation agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: choroidal neovascularization in each treatment group
Study: 11097147
Drug: DIC‐effervesc (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIC‐effervesc (50 mg diclofenac Na)
Study: 11097147
Drug: DIC‐enteric (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIC‐enteric (50 mg diclofenac Na)
Study: 9133184
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg neostigmine (group N25)
Study: 9133184
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg edrophonium (group E25)
Study: 9133184
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg neostigmine (group N5)
Study: 9133184
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg edrophonium (group E5)
Study: 7756472
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (300 mg every 4 weeks)
Study: 8442918
Drug: Cotrimoxazole (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (160/800 mg 3 days a week)
Study: 8442918
Drug: Dapsone plus
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone plus pyrimethamine (100 and 25 mg weekly)
Study: 24993763
Drug: Internet-delivered Acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Acceptance and Commitment Therapy (ACT) intervention, 8 sessions over 8 weeks
Study: 20880720
Drug: EMG‐BF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG‐BF treatment
Study: 10440593
Drug: PPA 12.5
Normalized name: APAP 325/CTM 2/PPA 12.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 12.5 mg tid
Study: 10440593
Drug: PPA 25
Normalized name: APAP 650/CTM 4/PPA 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 25 mg tid
Study: 10440593
Drug: Pseudoephedrine 120
Normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg/day
Study: 10440593
Drug: PPA 75
Normalized name: Guaifenex PPA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 75 mg/day with benzocaine gum 96 mg/day
Study: 10440593
Drug: Benzocaine gum
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzocaine gum 96 mg/day
Study: 15504857
Drug: Caspofungin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin alone (50 mg IV once daily)
Study: 15504857
Drug: Caspofungin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin with nelfinavir (1,250 mg orally twice daily)
Study: 15504857
Drug: Caspofungin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin with rifampin (600 mg orally once daily)
Study: 15504857
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg orally once daily)
Study: 15504857
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg daily)
Study: 9013456
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia)
Study: 9013456
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (Ganciclovir administered intravenously for 21 days upon detection of CMV viremia associated with a CMV syndrome)
Study: 9013456
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (Ganciclovir use)
Study: 9013456
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (Ganciclovir use)
Study: 9013456
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy (CMV-associated charges)
Study: 9013456
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (CMV-associated charges)
Study: 6374539
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline
Study: 26747128
Drug: modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint‐induced movement therapy (mCIMT) for 3 weeks
Study: 19666912
Drug: Early immunosuppressive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early immunosuppressive therapy (cyclophosphamide for 12 months, and steroids)
Study: 19666912
Drug: Late immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late immunosuppressive therapy (initiated when renal function deteriorated)
Study: 16479390
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (split GFR between 20 and 30 ml/min)
Study: 15364875
Drug: TP10 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP10 (1, 3, 5, 10 mg/kg)
Study: 8841220
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of saline plus epinephrine 1:200,000
Study: 8841220
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of oral ketoprofen preoperatively and mesosalpinx infiltration with 5 mL of bupivacaine 0.5% with epinephrine 1:200,000
Study: 8841220
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule with mesosalpinx infiltration
Study: 8841220
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preoperative ketoprofen and mesosalpinx block
Study: 6741677
Drug: Program adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program adherence post-treatment
Study: 30922101
Drug: Repeated ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated ketamine infusions (six infusions administered thrice weekly over 2 weeks)
Study: 30922101
Drug: Weekly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly maintenance infusions (four additional infusions administered once weekly)
Study: 28854569
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no additional treatment, n = 235)
Study: 24843653
Drug: cilnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilnidipine (10 mg/day)
Study: 21906391
Drug: azelnidipine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: azelnidipine (16 mg/day)
Study: 16625987
Drug: Generic efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic efavirenz capsule (Ranbaxy-Efavirenz)
Study: 16625987
Drug: Innovator efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator efavirenz capsule (Sustiva)
Study: 15541407
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (600 microg)
Study: 8329255
Drug: Metoclopramide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.5 mg kg‐1
Study: 3539508
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 methyl sulphonylamide
Study: 3539508
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg PGE1 methyl ester
Study: 3539508
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 9-methylene PGE2 free acid
Study: 3539508
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 15-methyl PGF2 alpha
Study: 19065890
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Shehuang Paste (SHP) and colonic dialysis with herbal medicine
Study: 19065890
Drug: Conventional basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional basic therapy (placebo paste and colonic dialysis with normal saline)
Study: 12587536
Drug: Dopamine-agonist therapy
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine-agonist therapy
Study: 12587536
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (healthy controls and dopamine-agonist treated women)
Study: 7640116
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg i.v. given 10 min before induction of anaesthesia
Study: 7640116
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg i.v. group
Study: 797447
Drug: Dianhydrogalactitol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianhydrogalactitol (30 mg/m2/day for 5 days)
Study: 797447
Drug: VP-16-213 (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP-16-213 (130 mg/m2 on Days 1, 3, and 5)
Study: 31484582
Drug: Conventional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional administration of oxygen through a Venturi mask (Control)
Study: 28504995
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy without RIPC
Study: 25888246
Drug: HER2+ hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HER2+ hormone receptor-positive (HR+) patients
Study: 25888246
Drug: HER2+ hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HER2+ hormone receptor-negative (HR-) patients
Study: 23503449
Drug: Fasting conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting conditions (400 mg posaconazole)
Study: 23503449
Drug: Normal-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-fat meal (400 mg posaconazole)
Study: 23503449
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (400 mg posaconazole)
Study: 11126352
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy as part of an intervention program for childhood obesity, including behavior modification.
Study: 9004827
Drug: Actuarial approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actuarial approach to treatment benefits
Study: 31712013
Drug: Prostaglandin analogue
Normalized name: Prostaglandin analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin analogue (PGA) monotherapy (control group)
Study: 31712013
Drug: Washout group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout group (discontinue PGA monotherapy)
Study: 24573586
Drug: Simple ligation
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple ligation of the saphenous vein without sectioning of its arch (Group L)
Study: 12875580
Drug: Betahistine (BH)
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (BH) 48 mg daily
Study: 12875580
Drug: Flunarizine (FL)
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (FL) 10 mg daily
Study: 8854285
Drug: Essential fatty
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential fatty acids (EFA) supplementation (Linoleic acid 596 mg/day and alpha-linolenic acid 855 mg/day)
Study: 25789633
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (ASA) prophylaxis
Study: 25789633
Drug: Control event
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Control event rate (CERmin) and minimum event rate for treatment (MERT) approaches
Study: 11004426
Drug: Diamicron(R)MR (30-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamicron(R)MR (30-120 mg/day)
Study: 11004426
Drug: Diamicron(R) (80-320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamicron(R) (80-320 mg/day)
Study: 8608520
Drug: Imipenem plus
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem plus vancomycin (500 mg every 6 hours of imipenem/cilastatin and 1 g every 12 hours of vancomycin)
Study: 8608520
Drug: Aztreonam plus
Normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aztreonam plus vancomycin (2 g every 6 hours of aztreonam and 1 g every 12 hours of vancomycin)
Study: 31818409
Drug: Isatuximab plus
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab plus pomalidomide and low‐dose dexamethasone